טוען...
Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes
AIMS/INTRODUCTION: Ultra‐rapid lispro (URLi) is a novel ultra‐rapid mealtime insulin. This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog(®)) in Japanese patients with type 1 diabetes mellitus. MATERIALS AND METHODS: This was a phas...
שמור ב:
| הוצא לאור ב: | J Diabetes Investig |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7232298/ https://ncbi.nlm.nih.gov/pubmed/31816193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13195 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|